A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use

The analyses demonstrate that indacaterol dominates both tiotropium and salmeterol in the base case and is likely to remain cost-effective under a range of assumptions. </AbstractSection> Copyright The Author(s) 2013

MoreLess

Year of publication:	2013
Authors:	Price, David ; Asukai, Yumi ; Ananthapavan, Jaithri ; Malcolm, Bill ; Radwan, Amr ; Keyzor, Ian
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 11.2013, 3, p. 259-274
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011000711